GPS Maintenance Therapy in AML Remission

REGAL Phase 3 of galinpepimut-S in AML maintenance has a 5-year OS endpoint; primary completion Nov 2026 makes statistically significant OS readout by that date unlikely given enrollment timeline and event accrual. Prior Phase 2 signals were modest, WT1 vaccine class has weak Phase 3 track record (e.g., galinpepimut MPM failure). Operational/disclosure risk and small-sponsor execution further reduce odds.

Phase 3 and active-not-recruiting reduce execution risk, and OS is a clean hard endpoint. But AML remission maintenance is heterogeneous, best-available-therapy control can dilute effect, and showing statistically significant OS by the cutoff is demanding for a vaccine-like maintenance approach.

Phase 3 AML maintenance trial with OS primary endpoint versus BAT; vaccine approach in high-risk population, hard endpoint, 5-year follow-up; no positive signals in provided trial fields on prior efficacy or powering.

GPS is a WT1 peptide vaccine, a class with a historically poor Phase 3 track record in AML. The pooled median OS of >13.5 months far exceeds the 6-month historical assumption, strongly suggesting the control arm (which allows venetoclax) heavily overperformed. This likely erodes the statistical power of the 80-event design, making a statistically significant OS improvement very unlikely.

Phase 3 of GPS vaccine in AML CR1 maintenance. Prior Phase 2 showed promising OS in small cohort, but larger Phase 3 in CR2/high-risk failed for futility. Cancer vaccines have high Phase 3 failure rate. OS endpoint requires many events; trial may be underpowered. Low probability of success.

GPS targets WT1 in AML maintenance but cancer vaccines have a poor Phase 3 track record. Phase 2 signals were modest, and achieving statistically significant OS benefit over best available therapy is a high bar. Small sponsor adds operational risk. Trial is 159 days from primary completion with 5-year OS endpoint—ambitious timeline. Intrinsic odds favor failure.

Phase 3 AML maintenance trials face high hurdles for OS benefit. SELLAS has a history of mixed results. GPS mechanism is promising but unproven in this setting. Best available therapy control arm is strong. Statistical significance for OS is difficult to achieve in this population, making failure more likely than success.

Phase‑3 AML maintenance trial; OS over 5 years is a stringent endpoint. GPS has early activity but AML relapse rates are high and maintenance benefits are historically modest, creating substantial uncertainty. Trial is active not recruiting, indicating enrollment complete but data pending, leading to a modest intrinsic success chance.

AML maintenance vaccine versus best available therapy with 5-year OS endpoint. Cancer vaccines have weak Phase 3 track record in hematologic malignancies. Active Not Recruiting status without disclosed interim efficacy suggests trial is proceeding to final readout without early stopping. Small-cap sponsor adds execution risk. Probability of statistically significant OS benefit is low.

Phase 3 AML maintenance with 5-year OS endpoint is highly ambitious. GPS targets WT1 but prior data not provided. Flexible comparator (best available therapy) complicates benefit demonstration. AML maintenance trials historically show modest effect sizes. Market price of 22% seems broadly fair given execution risk and ambitious primary endpoint. Intrinsic estimate: ~20%.